**What is already known**

Reversible cerebral vasoconstriction syndrome remains an under recognized cause of thunderclap headache that shares a similar history with subarachnoid hemorrhage.

**What is new in the current study**

This study evaluated the clinical manifestations, radiological features, and outcomes of patients with reversible cerebral vasoconstriction syndrome. It also focused on the average number of visits to the physicians before an accurate diagnosis and the mean duration of symptoms until diagnosis revealing a significant under recognition of reversible cerebral vasoconstriction syndrome.

INTRODUCTION
============

Headache is are classified as primary headache syndromes or headaches as a secondary effect \[[@b1-ceem-15-099]-[@b3-ceem-15-099]\]. Most emergency physicians focus on detecting life threatening conditions in patients with headaches \[[@b2-ceem-15-099]\]. As stated in the guidelines published by the American College of Emergency Physicians Clinical Policy for Adults with Headache in 2008, the history of the patient plays a major role in evaluation \[[@b4-ceem-15-099]\]. Thunderclap headache is a sudden-onset, severe headache that reaches maximal intensity within minutes. It can be associated with serious secondary etiologies that have high mortality rates, such as intracranial aneurysm, subarachnoid hemorrhage (SAH), cervical artery dissection, and ischemic stroke \[[@b5-ceem-15-099],[@b6-ceem-15-099]\]. However, the recently defined RCVS remains an underestimated cause of thunderclap headache and shares similar characteristics with SAH, particularly in terms of history \[[@b7-ceem-15-099]-[@b14-ceem-15-099]\]. Although the prognosis of RCVS has been reported to be generally favorable, fatal complications such as seizure, stroke, and SAH can occur a few days after diagnosis, and cerebral vasoconstriction reaches its maximum 2 to 3 weeks after clinical onset \[[@b4-ceem-15-099],[@b7-ceem-15-099]-[@b11-ceem-15-099],[@b15-ceem-15-099]-[@b19-ceem-15-099]\]. Moreover, the result in patients being subjected to unnecessary invasive testing and immunosuppressive therapy \[[@b7-ceem-15-099],[@b13-ceem-15-099]\].

This study evaluated the clinical manifestations, radiological features, and the outcomes of patients with RCVS at an emergency department (ED) with the aim of enabling physicians to maintain a high index of suspicion for RCVS and thereby leading to detection in more patients with thunderclap headache by thorough history taking during initial visits when there is no evidence of aneurysmal SAH.

METHODS
=======

We retrospectively reviewed the records of ED patients who presented with thunderclap headache and underwent cerebral head angiography at our medical center between January 2013 and December 2014. Before the beginning of this study, the institutional review board approved our review of patient data and waived the requirement for informed consent.

The diagnostic criteria for RCVS used in this study were based on proposed clinical, laboratory, and radiographic findings ([Table 1](#t1-ceem-15-099){ref-type="table"}) \[[@b8-ceem-15-099]\] with some recent modifications. Diagnosis of RCVS was made following the International Classification of Headache Disorders, 3rd edition, 2013, for headaches attributed to RCVS (code 6.7.3) ([Table 2](#t2-ceem-15-099){ref-type="table"}) \[[@b1-ceem-15-099]\]. We excluded patients who had experienced cerebral aneurysms, cerebrovascular malformations, brain tumors, strokes, and brain hemorrhage not related to RCVS. We also excluded patients with no evidence of cerebral vasoconstriction detected by cerebral head angiography at the time of their ED visit.

To investigate the clinical manifestations, radiological features, and outcomes of RCVS, we reviewed the baseline data of patients including age, sex, medical history, headache characteristics, duration of symptoms, and relevant laboratory and imaging results. Continuous variables are expressed as means with standard deviations, or as medians and full ranges if the assumption of a normal distribution was violated. Categorical variables are presented as numbers and percentages.

RESULTS
=======

Clinical features
-----------------

After excluding patients according to the exclusion criteria, 18 patients were diagnosed as RCVS on the basis of clinical and radiographic findings. Three patients were men; the average age was 50.7 years at the first ED visit, ranging from 16 to 63 years. Some patients had hyperlipidemia, one had chronic hepatitis B virus infection, one had chronic kidney disease, and one had hypothyroidism. Two patients were taking steroids because of Takayasu's arteritis and rheumatic arthritis. Two patients were taking hormonal agents, but both of them started taking the pills to relieve their pain after their severe headaches began. Before an accurate diagnosis, their headaches were misdiagnosed as postmenopausal symptoms. Other than these seven patients, 11 patients did not have any past medical histories. Only one patient had habitual headache episodes and the other 17 patients reported never experiencing headaches in their lifetime ([Table 3](#t3-ceem-15-099){ref-type="table"}). We reviewed the study population for the conditions associated with RCVS, such as pregnancy-related conditions (late pregnancy, early puerperium, pre-eclampsia, and eclampsia); blood product transfusion; surgical procedures; and exposure to various vasoactive medications such as oral contraceptive pills, hormonal agents, selective serotonin reuptake inhibitors, alpha-sympathomimetic decongestants, illicit drugs, and acute migraine medications were reviewed, but no patients reported having these conditions or taking such medications. The mean duration of symptoms until diagnosis was 9.3 days, ranging from 2 hours to 1 month. The average number of ambulatory care visits before diagnosis was 4.7, ranging from 1 to 6.

Headache profiles
-----------------

Four patients reported a headache in the middle of the vertex, four in the occipital area, three in the frontal area, and seven over the entire head. Six patients described pulsating headaches, and 11 reported explosive headaches. Seventeen patients, excluding one who reported a pain intensity of 6, experienced severe headaches (pain intensities of 8 to 10 on a numerical rating scale). All patients reported sudden severe headaches that reached maximum intensity within minutes and were sustained for 30 minutes to several hours with residual moderate headaches between the severe exacerbations. Painkillers reduced the intensity of pain but did not eliminate it completely. Patients had to take painkillers over time because the headaches were not relieved easily with non-steroidal anti-inflammatory drugs or acetaminophen. No patient had aura preceding the headache attacks. Nausea and vomiting were reported at the onset of headache in seven patients. Eleven patients reported that strenuous exercise, sexual activity, coughing, defecating, urinating, gagging, or other Valsalva triggering maneuvers exacerbated the headaches. Identified triggering factors in our study were tooth brushing, drinking beer, eating wasabi, swimming, and exposure to cold weather. Even though no patients had a history of hypertension, 15 patients had acute blood pressure elevation during triage, which may have been secondary to pain ([Table 4](#t4-ceem-15-099){ref-type="table"}).

Radiographic findings and clinical course
-----------------------------------------

Focal neurological deficits and seizures were not observed in any patients. The most frequently affected vessels were the middle cerebral arteries. Computed tomography (CT) angiography of the brain performed in 17 patients demonstrated the characteristic diffuse "string of beads" appearance in the middle cerebral arteries ([Figs. 1](#f1-ceem-15-099){ref-type="fig"}, [2](#f2-ceem-15-099){ref-type="fig"}). The anterior circulation was affected in nine patients and the posterior circulation in six. In 15 patients (except patients 1, 2, and 18), ancillary serum laboratory investigations were performed, including blood count, electrolyte levels, hepatic and renal function tests, erythrocyte sedimentation rate, C-reactive protein level, antinuclear and antineutrophil cytoplasmic antibody, and rheumatoid factor to exclude underlying connective tissue disorders such as infectious arteritis and inflammatory vasculitis, which share the radiological findings of RCVS. Patients 4, 6, and 11 were positive for rheumatoid factors. Their follow up CT angiography on days 20, 12, and 18 demonstrated complete resolution of vasoconstriction. The time to resolution of symptom ranged from 2 days to 4 months, but most patients reported that their headache was resolved within 2 months. All patients were given analgesic medications and bed rest. Nimodipine was administered to 16 patients due to its anti-vasospastic properties. Patients 11 and 14 were not given nimodipine. The blood pressure of these two patients was too low to start calcium channel blocker therapy. All patients reported a monophasic course without new headaches after the clinical diagnosis of RCVS was made. Other than three patients who were lost to follow-up, 15 patients had neither neurologic sequelae nor chronic headaches ([Table 5](#t5-ceem-15-099){ref-type="table"}).

DISCUSSION
==========

RCVS is characterized by acute, severe headaches with or without additional neurological deficits, often triggered by sexual activity, exertion, Valsalva maneuvers, emotion, and constriction of the cerebral arteries that resolves spontaneously within 12 weeks \[[@b1-ceem-15-099],[@b7-ceem-15-099],[@b10-ceem-15-099],[@b11-ceem-15-099],[@b13-ceem-15-099],[@b20-ceem-15-099]-[@b22-ceem-15-099]\]. The diagnostic criteria are based on clinical, laboratory, and radiographic findings ([Table 1](#t1-ceem-15-099){ref-type="table"}) \[[@b1-ceem-15-099]\] and have been modified recently ([Table 2](#t2-ceem-15-099){ref-type="table"}) \[[@b1-ceem-15-099],[@b7-ceem-15-099],[@b15-ceem-15-099]\].

The exact incidence of RCVS is unknown, but it does not seem to be especially rare \[[@b7-ceem-15-099],[@b13-ceem-15-099]\]. Its incidence is estimated to be between 8.8% and 45.8% in patients with thunderclap headache and those without an obvious secondary cause of headache \[[@b12-ceem-15-099],[@b23-ceem-15-099]\]. However, it might be underestimated because there is no research reporting the incidence of RCVS in ED patients, the most common mode of entry for patients presenting with thunderclap headache.

The characteristics of headaches associated with RCVS are severe pain that peaks in minutes, causing screaming, crying, agitation, and even collapse. For these reasons, it can often be confused with a ruptured aneurysm \[[@b24-ceem-15-099],[@b25-ceem-15-099]\]. Nausea, vomiting, photophobia, and phonophobia frequently accompany the headaches \[[@b8-ceem-15-099],[@b10-ceem-15-099],[@b11-ceem-15-099],[@b23-ceem-15-099]-[@b27-ceem-15-099]\]. The headache is mostly moderate in severity between exacerbations \[[@b7-ceem-15-099]\]. Headaches caused by RCVS are not relieved easily with nonsteroidal anti-inflammatory drugs or acetaminophen, which are the initial recommendations for primary headaches. This causes patients to repeatedly visit doctors seeking relief from the severe pain. In our study, patients with RCVS visited an average of 4.7 physicians before receiving an accurate diagnosis.

In one study by Ducros et al. \[[@b26-ceem-15-099]\], vasoconstriction was detected at a mean of 8 days after headache onset, and up to 14 days in some patients. According to the present study, the mean duration of symptoms until diagnosis was 9.3 days. The results reveal that the incidence of RCVS is significantly underestimated and highlight the need for emergency physicians to be aware of RCVS in patients with severe-onset headaches.

Cerebral head angiography is essential for diagnosing RCVS \[[@b14-ceem-15-099]\]. CT angiography images of our patients showed multifocal segmental narrowing and dilatation of the cerebral arteries. Follow-up CT angiography showed complete regression of vasoconstriction.

The present study was limited by its retrospective nature, the small number of patients included, and the lack of a control group. Further study will be needed to evaluate the treatment of RCVS.

ED physicians should maintain a high index of suspicion for RCVS in order to improve its detection rates in patients with thunderclap headache when there is no evidence of aneurysmal SAH, not only because of its relatively high incidence and clinical manifestation of severe headache, but also because of the easy accessibility of newer, relatively noninvasive technologies such as CT angiography and magnetic resonance angiography to assess the cerebral vasculature. Furthermore, early recognition is important so that symptoms can be managed effectively with the elimination of precipitating factors and unfavorable complications such as seizure, stroke, and SAH.

No potential conflict of interest relevant to this article was reported.

![A computed tomography angiography image of patient 17 on day 7 showing multifocal arterial narrowing of the cerebral arteries.](ceem-15-099f1){#f1-ceem-15-099}

![A transfemoral cerebral angiography image of patient 17 showing multifocal arterial narrowing of the cerebral arteries.](ceem-15-099f2){#f2-ceem-15-099}

###### 

Diagnostic criteria for reversible cerebral vasoconstriction syndrome

  The elements of diagnosis
  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Acute severe headache (often thunderclap headache) with or without focal deficits or seizures
  Uniphasic course without new symptoms more than a month after clinical onset
  Segmental vasoconstriction of cerebral arteries shown by indirect (e.g., magnetic resonance and computed tomography) or direct catheter angiography
  No evidence of aneurysmal subarachnoid hemorrhage
  Normal or near-normal cerebrospinal fluid (protein concentration \<100 mg/dL, \<15 white blood cells/μL, normal glucose)
  Complete or substantial normalization of arteries shown by follow-up angiography (indirect or direct) within 12 weeks of clinical onset

The criteria proposed in 2007 by Calabrese et al. \[[@b8-ceem-15-099]\].

###### 

Diagnostic criteria: headache attributed to reversible cerebral vasoconstriction syndrome

  The elements of diagnosis
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A. Any new headache fulfilling criterion C
  B. Reversible cerebral vasoconstriction syndrome has been diagnosed
  C. Evidence of causation demonstrated by at least one of the following:
   1. Headache, with or without focal deficits and/or seizures, has led to the performance of angiography (with 'strings and beads' appearance) and a diagnosis of reversible cerebral vasoconstriction syndrome.
   2. Headache has either or both of the following characteristics:
    a) Recurrent during 1 month and with thunderclap onset
    b) Triggered by sexual activity, exertion, Valsalva maneuvers, emotion, bathing, and/or showering
   3. No new significant headache occurs \>1 month after onset
  D. Not better accounted for by another International Classification of Headache Disorders, 3rd edition, diagnosis, and aneurysmal subarachnoid hemorrhage has been excluded by appropriate investigations.

The criteria of the International Classification of Headache Disorders, 3rd edition, 2013 \[[@b1-ceem-15-099]\].

###### 

Characteristics of the study patients

  Patient no.   Age (yr)   Sex   Past medical history        Current medication   Habitual headache episodes   Symptom duration until diagnosis   No. of ambulatory care visits before diagnosis
  ------------- ---------- ----- --------------------------- -------------------- ---------------------------- ---------------------------------- ------------------------------------------------
  1             55         F     Hyperlipidemia              Hormone therapy      No                           7 days                             3
                                 For 3 days                                                                                                       
  2             30         M     Hepatitis B virus carrier   Hepsera              No                           5 days                             1
  3             58         F     Hypothyroidism              Synthroid            No                           10 days                            5
  4             49         F     Rheumatic arthritis         Prednisolone         No                           10 days                            5
  5             52         F     None                        Hormone therapy      No                           1 mo                               3
                                 For 10 days                                                                                                      
  6             57         F     None                        None                 No                           7 days                             5
  7             16         F     Takayasu's arteritis        Prednisolone         No                           4 days                             1
  8             55         F     None                        None                 No                           2 hr                               1
  9             51         M     None                        None                 No                           12 days                            2
  10            39         M     None                        None                 No                           3 days                             5
  11            58         F     Chronic kidney disease      None                 No                           4 days                             3
  12            61         F     Hyperlipidemia              None                 No                           10 days                            3
  13            52         F     None                        None                 No                           5 days                             3
  14            56         F     None                        None                 Yes                          2 days                             2
  15            63         F     None                        None                 No                           3 days                             3
  16            52         F     None                        None                 No                           9 days                             3
  17            51         F     None                        None                 No                           7 days                             6
  18            58         F     None                        None                 No                           3 days                             3

###### 

Headache profiles of the study patients

  Patient no.   Pain severity    Pain location   Character   Associated symptoms   Aggravating factors           Blood pressure in the emergency department
  ------------- ---------------- --------------- ----------- --------------------- ----------------------------- --------------------------------------------
  1             8                Vertex          Explosive    None                 Cold                          142/88
  2             10               Diffuse         Pulsatile    Nausea               Defecation                    177/103
  3             10               Vertex          Explosive    Nausea               Defecation, coughing          133/86
  4             9                Frontal         Explosive    Nausea               Leaning forward, urination    159/101
                 Ocular pain                                                                                     
  5             10               Frontal         Pulsatile    Nausea               Leaning forward, defecation   189/112
                 Ocular pain                                                                                     
  6             10               Diffuse         Pulsatile    None                 None                          145/82
  7             8                Occipital       Explosive    None                 None                          124/82
  8             8                Frontal         Tension      Vomiting             None                          121/77
  9             8                Diffuse         Explosive    Dizziness            Sexual activity               129/94
  10            8                Vertex          Explosive    None                 None                          144/93
  11            8                Vertex          Pulsatile    Nausea               Valsalva                      188/88
                 Vomiting        Swimming                                                                        
  12            10               Diffuse         Explosive    Phonophobia          Coughing, urination           153/120
  13            9                Diffuse         Explosive    None                 Gagging, swimming             155/96
  14            6                Occipital       Explosive    None                 Defecation                    167/97
  15            10               Diffuse         Explosive    None                 Wasabi intake                 163/95
                Tooth brushing                                                                                   
  16            10               Diffuse         Explosive    Nausea               Leaning forward               152/95
  17            10               Occipital       Pulsatile    Nausea               Drinking beer                 138/97
  18            10               Occipital       Pulsatile    None                 Leaning forward, defecation   180/89

###### 

Computed tomography angiography manifestations and clinical courses of the study patients

  Patient no.   Site of vasoconstriction   CSF findings   Treatment    Complication   Time to symptom resolution   Prognosis
  ------------- -------------------------- -------------- ------------ -------------- ---------------------------- -------------------
  1             Both MCA                   Not done       Nimodipine   No             \< 1 mo                      Favorable
  2             Both MCA, ACA              Clear          Nimodipine   No             Unknown                      Lost to follow up
                Right PCA                                                                                          
  3             Both MCA                   Clear          Nimodipine   No             \< 1 mo                      Favorable
  4             Both MCA, ACA              RBC (+)        Nimodipine   SAH            \< 2 mo                      Favorable
                Right PCA                                                                                          
  5             Left MCA                   Not done       Nimodipine   SAH            \< 1 mo                      Favorable
                Both ACA                                                                                           
  6             Both ICA, right ACA, PCA   Not done       Nimodipine   No             \< 1 mo                      Favorable
  7             Left MCA                   Not done       Nimodipine   No             \< 1 mo                      Favorable
  8             Both MCA                   Not done       Nimodipine   No             \< 2 day                     Lost to follow up
  9             Both MCA                   Not done       Nimodipine   No             \< 1 mo                      Favorable
  10            Right MCA                  Clear          Nimodipine   No             \< 1 mo                      Favorable
  11            Both ACA                   Clear          (-)          No             \< 3 mo                      Favorable
                Right MCA, PCA                                                                                     
  12            Both MCA Right ACA         Clear          Nimodipine   No             \< 4 mo                      Lost to follow up
  13            Both MCA                   RBC (+)        Nimodipine   SAH            \< 4 mo                      Favorable
  14            Both MCA, ACA              Clear          (-)          No             \< 1 mo                      Favorable
  15            Both MCA                   Clear          Nimodipine   No             \< 2 mo                      Favorable
  16            Both PCA                   Clear          Nimodipine   No             \< 1 mo                      Favorable
                Left MCA, PICA                                                                                     
  17            Both MCA, ACA, PCA         Not done       Nimodipine   SAH            \< 2 mo                      Favorable
  18            Right MCA                  Not done       Nimodipine   No             \< 2 mo                      Favorable

CSF, Cerebrospinal fluid; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; SAH, subarachnoid hemorrhage; ICA, internal carotid artery; PICA, posterior inferior cerebellar artery.
